Perspectives in Pharmacoeconomic Evaluation L3 Part 1

Perspectives in
Pharmacoeconomic evaluation
L3 PART 1
0204420
PERSPECTIVES IN PE STUDIES
•Perspectives are the point of view from

which an economic analysis is performed.
Why perspective are important in PE?
• A health intervention that looks unattractive from one perspectives
might look attractive from different point view e.g. Class substitution
of simvastatin with atorvastatin
• Patient perspective: can be taken any time on the day, less frequent to
forget and might be more expensive
• Health insurance company: not first line and more expensive
Why perspective are important in PE?
• The perspective of PE describes and determines the
categories of costs and consequences to be
identified, measured, and valued E.g. New outpatient
procedure
• From governmental perspective: costs related to
direct medical costs and indirect only
• From patient perspective: cost related to direct non-
medical
PERSPECTIVES IN PE STUDIES
• An economic evaluation can be conducted from a single perspective,
or multiple perspectives
• Types of perspectives :
• Societal perspective
• Provider perspective (e.g. hospital)
• Patient perspective
• Payer perspective (e.g. health insurance company)
Societal perspective: MONDAY section 62
• the broadest of all viewpoints
• Considers all the benefits/costs to the society as a whole
• All direct and indirect costs are included
• Irrespective of whose responsibility it is to pay for the costs
• In the US, societal perspective is recommended
Provider Perspective
• True (actual) expense of providing a product or
service
• Regardless of how much they charge for that
product or service
• E.g. hospitals, dispensaries (polyclinics) or
private practice physicians
Patient perspective:
• what patients (i.e. the ultimate consumers of health
care services) pay for a product or service
• The portion not covered by insurance
• Out of patient pocket expenses
• Indirect costs (lose of productivity)
Payer perspective:
• charges for health care products and services allowed, or reimbursed,
by the payer.
• Payer may be insurance companies, or employers
• In the UK NHS perspective

• e.g. Cost of hospital care, medication, pharmacist and doctor time,
nurse visit
CHECK YOUR UNDERSTANDING
• Which of these costs will be considered from Hospital (provider)
perspective?
• Prescriber time
• Time in hospital
• Drug costs
• Time off work
• Out of pocket transport expenses
• Time to dispense the medicines
CHECK YOUR UNDERSTANDING
• The costs of Drug A, on average
• Drug costs =10,000 USDs over 10 years
• Prevent 5 doctor visits/ over 10 years = 500 USDs
• Prevent 1 hospitalisation/ over 10 years = 2000 USDs
• Saves 10 working days/ over 10 years = 2000 USDs
• What would be the cost from:

• • Payer perspective (e.g. health insurance company)?
• • Societal perspective ?
•Answers
••Payer perspective (e.g. health
insurance company)? USDs7,500
••Societal perspective ? USDs5,500
EXAMPLE FROM LITERATURE (1)
• Cull R et al., Economic costs of migraine Br J Med Econ 1992;5:103-
115
• A study of migraine which took the health service perspective only
might suggest that sumatriptan in migraine (an expensive drug in an
area which previously cost the health service very little) was highly
undesirable, but a study taking a societal perspective might come to
the opposite conclusion.
EXAMPLE FROM LITERATURE (2)
• Example: Comparing laparoscopic cholecystectomy versus open
cholecystectomy
• Different methods to remove the gallbladder
• Laparoscopic cholecystectomy was a new technique
• Health outcomes for the two techniques were considered equivalent
• Hospital and societal perspectives reported??
Berggen et al. 1996
What do you think?
• Societal viewpoint
• – Laparoscopic surgery was cheaper
• Hospital viewpoint
• – Excluding effects on production
• – Laparoscopic surgery was more expensive

Perspectives in Pharmacoeconomic Evaluation L3 Part 1

Uploaded by

Perspectives in Pharmacoeconomic Evaluation L3 Part 1

Uploaded by

Perspectives in

•Perspectives are the point of view from

• Payer may be insurance companies, or employers

• In the UK NHS perspective

• What would be the cost from:

You might also like